S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial

Sang-Ho Jo 1, Sung-Ji Park 2, Eung Ju Kim 3, Soo-Joong Kim 4, Hyun-Jae Cho 5, Jong-Min Song 6, Jinho Shin 7, Jin Joo Park 8, Joon-Han Shin 9, Kyoo-Rok Han 10 and Dong-Ju Choi 8*

Abstract

Background: The efficacy of a combination of a calcium channel blocker (CCB) plus chlorthalidone (diuretic) versus a CCB plus an angiotensin receptor blocker (ARB) in patients not responding to CCB monotherapy has not been evaluated previously. We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy.

Methods/design: This study is a prospective, randomized, double-blind, multicenter, parallel, non-inferiority phase 4 study. Hypertension patients who have been treated with amlodipine (5 mg) or S-amlodipine (2.5 mg) monotherapy for ≥2 weeks and whose mean diastolic blood pressure (DBP) is greater than 90 mmHg will be randomized to either S-amlodipine (2.5 mg) plus chlorthalidone (25 mg) or S-amlodipine (2.5 mg) plus telmisartan (40 mg) therapy. The primary efficacy endpoint is mean sitting DBP change after 12 weeks of treatment. The study objective is to prove the non-inferiority of the former combination (test drug) as compared to the latter one (control) with a non-inferiority margin of 3 mmHg in mean DBP change. The secondary endpoints are 6-week DBP change, 6- and 12-week sitting systolic BP (SBP) change, and the attainment of the target BP (SBP < 140 mmHg or DBP < 90 mmHg). Urine albumin, albumin/creatinine ratio (ACR), pulse wave velocity, central BP, 24-h ambulatory BP monitoring, and body fluid composition analysis will be performed at each hospital’s discretion. The sample size was estimated as 170 in total with 1:1 randomization.

Discussion: This is the first study comparing the efficacy of a CCB plus chlorthalidone versus a CCB plus an ARB in patients who are not responding to CCB single therapy. The study result will help clinicians to choose between chlorthalidone and telmisartan in CCB-unresponsive patients.

Trial registration: ClinicalTrials.gov, NCT03226340. Registered on 2 December 2015.

Keywords: Hypertension, Combination, Calcium channel blocker, Angiotensin receptor blocker
Background
Hypertension is the most prevalent disease worldwide and a leading cause of cardiovascular mortality and morbidity [1]. Its treatment has proven prolonging survival and reducing heart disease and stroke [2].

Most patients with hypertension need to be treated with antihypertensive medication, and some require two or more antihypertensive drugs [3]. A Korean study reported that 46% of hypertension patients are treated with two or more drugs, 38% with two drugs, and 8% with three or more drugs [4]. Accordingly, it is important to determine the most appropriate combination of antihypertensive agents. However, clinical trials comparing each combination therapy are scarce.

In the representative large-scale ”Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH)” study, the efficacy of an angiotensin-converting enzyme inhibitor (ACEI) plus a calcium channel blocker (CCB) was compared with that of an ACEI plus a diuretic, and the study demonstrated the superiority of the former combination based on clinical outcomes, despite a similar blood pressure (BP) reduction in both groups [5].

Among possible two-drug combination regimens, the European Society of Cardiology (ESC) guideline on arterial hypertension recommends CCBs and diuretics as the central drugs for the combination [6]. The guideline suggests addition of ACEIs, angiotensin receptor blockers (ARBs), and diuretics to CCB monotherapy, and as add-on drugs to diuretics, ARBs, ACEIs, and CCBs are recommended. Considering the similarity between ACEIs and ARBs, we can assume the major three-combination regimens as ACEI/ARB + CCB, ACEI/ARB + diuretic, and CCB + diuretic.

Combination regimen comparisons other than that mentioned in the ACCOMPLISH study (ACEI/ARB + CCB versus ACEI/ARB + diuretic) are ([ACEI/ARB + CCB] versus [CCB + diuretic]) and ([ACEI/ARB + diuretic] versus [CCB + diuretic]). Our study deals with the former one.

Each drug of the CCB + diuretic combination (amlodipine/S-amlodipine and thiazide/chlorthalidone) has been extensively studied [7, 8], and the American and European guidelines on hypertension treatment recommend the combination of CCB + diuretic [9, 10]. This combination has demonstrated good efficacy and safety in some studies [11–13]. However, it is not as commonly used as the renin–angiotensin–aldosterone antagonist-based combination. The CCB + diuretic combination has only been compared with combinations, such as beta-blocker + diuretic [14] and ARB + diuretic [15], in large-scale clinical trials. A randomized clinical trial investigated the difference between CCB + diuretic and CCB + ARB combinations by comparing three regimens: benidipine + thiazide diuretic, benidipine + ARB, and benidipine + beta-blocker, and cardiovascular outcomes and BP-lowering effects with benidipine + thiazide and benidipine + ARB were similar [16]. In contrast to hydrochlorothiazide used in this reported trial, we have chosen chlorthalidone as the diuretic as it is associated with better clinical outcomes and BP-lowering efficacy and lower adverse effects than hydrochlorothiazide; however, this report is controversial [17, 18]. In fact, chlorthalidone is rarely used in Korea and hydrochlorothiazide is the most commonly used diuretic. Accordingly, there is a lack of data regarding single and combination therapies with chlorthalidone in Korea.

In this clinical trial, we plan to compare the efficacy and safety between S-amlodipine plus chlorthalidone (diuretic) combination as the test combination regimen and S-amlodipine plus telmisartan (ARB) as control in patients with hypertension who do not adequately respond to CCB monotherapy.

Methods/design
Overall design
This study is a prospective, randomized, double-blind, multicenter, parallel, non-inferiority phase 4 study to compare the efficacy and safety between S-amlodipine plus chlorthalidone (diuretic) and S-amlodipine plus telmisartan combination therapies in patients with hypertension who do not adequately respond to CCB monotherapy.

Ten tertiary university hospitals in Korea are to participate in this study. Patients with essential hypertension who have a medical history of treatment with amlodipine (5 mg) or S-amlodipine (2.5 mg) monotherapy for ≥2 weeks prior to screening and whose mean sitting diastolic BP (DBP) is >90 mmHg are considered as potential subjects for this study. Those who have completed the final compatibility evaluation will be randomly assigned to either the test group (S-amlodipine 2.5 mg + chlorthalidone 25 mg) or the control group (S-amlodipine 2.5 mg + telmisartan 40 mg) in a 1:1 ratio. The study subjects in both groups will receive an oral dose of the test or control drugs plus a matching placebo once daily for a total of 12 weeks and will be evaluated for safety and efficacy. They will visit the outpatient clinic three times, including screening during the study period (Fig. 1).

The trial is approved by the relevant institutional review board of each center and is registered at ClinicalTrials.gov (identifier no. NCT03226340).

For a detailed overview, see the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure (Fig. 2). The SPIRIT checklist is provided as Additional file 1.
Fig. 1 Overall scheme of the study

Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
Study objective
The study aim is to demonstrate the non-inferiority (non-inferiority margin of 3 mmHg in DBP) of the S-amlodipine plus chlorthalidone combination therapy compared to the S-amlodipine plus telmisartan combination therapy in patients whose BP is not controlled with amlodipine monotherapy.

Patients

Inclusion criteria
1. Male and female patients with essential hypertension, aged between 18 and 80 years.
2. Patients who are confirmed to be treated with amlodipine or S-amlodipine monotherapy for ≥ 2 weeks immediately prior to screening.
3. Patients whose mean sitting DBP is > 90 mmHg, which is confirmed by triplicate measurements from the reference arm at screening.
4. Patients who have signed the informed consent by the study associate.

Exclusion criteria
1. Patients with a history of secondary hypertension and suspected secondary hypertension including coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing’s syndrome, pheochromocytoma, and polycystic kidney disease.
2. Patients with a mean systolic BP (SBP) ≥ 200 mmHg or DBP ≥ 110 mmHg at the screening visit.
3. Patients with ≥ 20 mmHg difference between the highest and the lowest sitting SBP or ≥ 10 mmHg difference between the highest and the lowest DBP, which is confirmed by triplicate measurements from the reference arm at screening.
4. Patients with uncontrolled diabetes (HbA1c ≥ 9.0%).
5. Patients who have been continuously taking other medicines, such as systemic steroids, thyroid hormones, oral contraceptives (except for menopausal hormone replacement therapy), psychiatric drugs, NSAIDs, sympathetic drugs, and immune suppressants, which have the potential to affect the BP.
6. Patients with symptomatic orthostatic hypotension.
7. Patients with a history of malignant tumors, including leukemia and lymphoma, within the past 5 years.
8. Patients with a history of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
9. Patients with a history of hypersensitivity to S-amlodipine nicotinate or other drugs containing chlorthalidone or telmisartan.
10. Patients with clinically significant kidney and liver diseases, such as those on dialysis, liver cirrhosis, biliary obstruction, and hepatic failure, or those who show the following findings at screening visit:
   - Alanine transaminase or aspartate transaminase level is at least three times higher than the normal upper limit.
   - Total bilirubin level is more than twice the normal upper limit.
   - Blood urea nitrogen level is more than twice the normal upper limit.
   - Alkaline phosphatase level is more than twice the normal upper limit.
   - Creatinine clearance level is less than 10 mL/min.
11. Patients with a history of the following diseases in the past 6 months, which are determined to be clinically significant by the investigator:
   - Heart failure (NYHA classes III and IV), ischemic heart diseases (coronary artery diseases, such as angina pectoris and myocardial infarction), peripheral vascular diseases, hemodynamically significant valve stenosis, and arrhythmia.
   - Severe cerebrovascular events, including stroke, cerebral infarction, and cerebral hemorrhage.
12. Patients with shock.
13. Patients with a history of alcohol or drug abuse.
14. Patients with potential pregnancy or who are breastfeeding.
15. Patients who are judged by the investigator to be inadequate to participate in the clinical study both legally and psychologically.
16. Patients who have participated in clinical studies with other investigational drug products within 4 weeks prior to screening.

Study drugs
The test drugs are a combination of Lodien tablet, 2.5 mg (S-amlodipine 2.5 mg, Hanlim Pharmaceutical Co., Ltd.) plus Hygroton tablet, 25 mg (chlorthalidone 25 mg, Hanlim Pharmaceutical Co., Ltd.). The control drugs are a combination of Lodien tablet, 2.5 mg plus Micardis tablet, 40 mg (telmisartan 40 mg, Boehringer Ingelheim Korea Co., Ltd.). The patients are recommended to take both the tablets (test or control drugs) and matching placebo (totally three tablets) at the same time once a day for 12 weeks (Fig. 1).

Endpoints
The primary endpoint is to demonstrate the non-inferiority of the S-amlodipine plus chlorthalidone combination therapy compared to the S-amlodipine plus telmisartan combination therapy based on the difference in sitting DBP after 12 weeks of treatment. The secondary endpoints are mean sitting DBP change at 6 weeks,
6- and 12-week sitting SBP change, and the attainment of the target BP (SBP < 140 mmHg or DBP < 90 mmHg) at 12 weeks.

**Investigational endpoint**
The following tests are to be carried out at the discretion of each investigator according to the availability of the medical devices for the measurement at the screening point and visit 3.

1. **Pulse wave velocity**
   
   Measurement of the left and right brachial–ankle pulse wave velocity.

2. **Central blood pressure**
   
   Waveforms directly to be measured from the carotid artery or by applying pressure to the radial artery using a sensor will be obtained using a general transfer formula.

3. **24-h ambulatory BP monitoring**
   
   The BP cuff will be wrapped around the upper arm and connected to a portable monitor for monitoring the BP for 24 h. The BP will be measured every 15 min during the day and every 30 min during the night, and the measurement interval can be defined differently.

4. **Body fluid composition analysis using InBody720**
   
   (body water, edema index)
   
   It will be automatically calculated and confirmed by the measuring equipment.

**Sample size estimation**

We have referred to two studies for sample size estimation. One study is regarding a combination therapy with chlorthalidone or valsartan as an add-on drug to diltiazem [19], and the other one compared amlodipine with hydrochlorothiazide versus telmisartan [20]. We have also referred to the Korea Ministry of Food and Drug Safety review data on amlodipine/telmisartan combination [21]. With these references, we calculated the number of patients by assuming the mean change in DBP will be equal in the intervention and control arms and the standard deviation of mean DBP change as 7.2 mmHg in the test group. The alpha error is estimated as 0.05 (one-tailed) and beta error as 0.2. The non-inferiority margin for DBP change in the clinical setting of hypertension is stated as 3 in the Guideline on Assessment by the Ministry of Food and Drug Safety [21]; therefore, we estimated the sample size as 72 and the final size as 85 in each group considering 15% patients will be lost to follow-up.

**Statistical analysis**

To identify inter-group difference in the demographic variables and the baseline information at the time point prior to the study initiation, continuous data will be compared by the two-sample t test or Wilcoxon’s rank sum test and categorical data by the chi-square test or Fisher’s exact test.

To verify that the mean DBP variation in the S-amlodipine 2.5 mg plus chlorthalidone 25 mg (test) group is non-inferior to that in the S-amlodipine 2.5 mg plus telmisartan 40 mg (control) group, the mean DBP change at week 12 post treatment from the baseline in the two groups will be obtained. If the lower limit of 95% confidence interval is larger than –3 mmHg using the one-tailed t test with a significance level of 0.05, the test drug combination would be considered non-inferior to the control drug combination.

Firstly, we will test the normality using the normal probability plot, a quantile–quantile plot (QQ plot), and perform the Kolmogorov–Smirnov test and Shapiro–Wilk test. If normality is not guaranteed, non-parametric tests such as the Mann–Whitney U test or Wilcoxon rank sum test will be applied.

Regarding adjustment for covariates, because this is a randomized controlled trial, we believe that the patient characteristics will be well balanced between the groups. However, should there be significant differences between groups, we will adjust for those variables during statistical analysis. ANCOVA will be conducted with the baseline DBP level as a covariate. If the lower limit of the 95% confidence interval for the difference by subtracting the change in the test group from that in the control group is greater than –3 mmHg after ANCOVA, the mean DBP decrease in the test group can be proven to be non-inferior to that in the control group.

**Randomization**

Randomization will be performed according to a pre-designed block randomization method. The randomization block will be generated by an independent statistician who is unrelated to this study using the SAS randomization program. Randomization will be performed in a 1:1 ratio in a consecutive order.

**Analysis**

**Intention-to-treat analysis set (full analysis set)**

Data from all subjects in both groups who are randomly assigned to the primary analysis of efficacy assessment will be subjected to intention-to-treat analysis assuming that the patients have taken the investigational products at least once, and the efficacy assessment will be
performed at least once after the time point of baseline evaluation and after the administration of the investigational products.

**Per-protocol analysis set**

In the per-protocol analysis set (PPS) that is subjected to the secondary analysis of efficacy assessment, any of the following subjects who are considered to present major deviations from the clinical study protocol will be excluded from the analysis.

1. Subjects who have not completed the period specified in the study protocol and have withdrawn early.
2. Study subjects whose medication compliance with the investigational products is less than 75%.
3. Study subjects who are determined to present major deviations from the study protocol.
4. Subjects who violate the inclusion/exclusion criteria.

**Safety set**

The subjects who are randomly assigned and have taken the investigational products at least once and whose safety-related data are confirmed via telephone or hospital visit by the investigator will be included in the safety set. Efficacy analysis will be conducted on the full analysis set (FAS) and the PPS. Demographic data will be obtained from the FAS, while safety assessment will be performed on the safety set.

In case of missing data at a certain time point or if the subject drops out before the close-out of the clinical study, the last observation carried forward (LOCF) method will be applied to verify the efficacy. The analysis is limited to patients for whom the efficacy assessment has been conducted once from the baseline. The safety analysis will be conducted with the raw data without applying the LOCF method.

**Discussion**

Multiple drug therapy ought to be considered by physicians to manage the BP adequately in hypertension patients. Although a number of studies have reported that two drugs or more are needed to control the BP adequately in hypertension patients, there are still situations, such as heart failure.

**Per-protocol analysis set**

In the per-protocol analysis set (PPS) that is subjected to the secondary analysis of efficacy assessment, any of the following subjects who are considered to present major deviations from the clinical study protocol will be excluded from the analysis.

1. Subjects who have not completed the period specified in the study protocol and have withdrawn early.
2. Study subjects whose medication compliance with the investigational products is less than 75%.
3. Study subjects who are determined to present major deviations from the study protocol.
4. Subjects who violate the inclusion/exclusion criteria.

**Safety set**

The subjects who are randomly assigned and have taken the investigational products at least once and whose safety-related data are confirmed via telephone or hospital visit by the investigator will be included in the safety set. Efficacy analysis will be conducted on the full analysis set (FAS) and the PPS. Demographic data will be obtained from the FAS, while safety assessment will be performed on the safety set.

In case of missing data at a certain time point or if the subject drops out before the close-out of the clinical study, the last observation carried forward (LOCF) method will be applied to verify the efficacy. The analysis is limited to patients for whom the efficacy assessment has been conducted once from the baseline. The safety analysis will be conducted with the raw data without applying the LOCF method.

**Per-protocol analysis set**

In the per-protocol analysis set (PPS) that is subjected to the secondary analysis of efficacy assessment, any of the following subjects who are considered to present major deviations from the clinical study protocol will be excluded from the analysis.

1. Subjects who have not completed the period specified in the study protocol and have withdrawn early.
2. Study subjects whose medication compliance with the investigational products is less than 75%.
3. Study subjects who are determined to present major deviations from the study protocol.
4. Subjects who violate the inclusion/exclusion criteria.

**Safety set**

The subjects who are randomly assigned and have taken the investigational products at least once and whose safety-related data are confirmed via telephone or hospital visit by the investigator will be included in the safety set. Efficacy analysis will be conducted on the full analysis set (FAS) and the PPS. Demographic data will be obtained from the FAS, while safety assessment will be performed on the safety set.

In case of missing data at a certain time point or if the subject drops out before the close-out of the clinical study, the last observation carried forward (LOCF) method will be applied to verify the efficacy. The analysis is limited to patients for whom the efficacy assessment has been conducted once from the baseline. The safety analysis will be conducted with the raw data without applying the LOCF method.

**Discussion**

Multiple drug therapy ought to be considered by physicians to manage the BP adequately in hypertension patients. Although a number of studies have reported that two drugs or more are needed to control the BP adequately in hypertension patients, there are still situations, such as heart failure.
between S-amlodipine + chlorthalidone and S-amlodipine + telmisartan and will facilitate the selection of the most appropriate combination regimen for treating patients not responding to single antihypertensive therapy. This study comparing S-amlodipine + chlorthalidone versus S-amlodipine + telmisartan in hypertensive patients whose BP is not controlled with amloidipine monotherapy will help clinicians to select the add-on drug for better controlling the BP in hypertension patients.

**Trial status**

The trial (ClinicalTrials.gov, identifier number: NCT03226340) is currently ongoing and is in the recruitment phase. Recruitment began on 2 December 2015 and is expected to finish in 2018.

**Additional file**

Additional file 1: SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 124 kb)

**Abbreviations**

ARB: Angiotensin receptor blocker; BP: Blood pressure; CCB: Calcium channel blocker; DBP: Diastolic blood pressure; ESC: European Society of Cardiology; FAS: Full analysis set; LOCF: Last observation carried forward; PPS: Per-protocol analysis set; SBP: Systolic blood pressure

**Acknowledgements**

This research was supported by Hanlim Pharmaceutical Co., Ltd, Korea, under the programs of the Seoul National University Bundang Hospital (SNUBH) research support (Subject No.: 06-2015-203 and IRB No.: B-1507/307-005) and was partly supported by the ITECH R&D program of MOTIE/KEIT (Project No. 10053597, Development of High-Speed Signal Processing IC and Platform for Contactless Monitoring of Bio-Signal in Vehicle).

**Authors’ contributions**

SHJ mainly wrote the manuscript. SHJ, SJP, EJK, KRH, and DJC made the overall design of the study. SKJ and HJC participated in statistical method planning. JMS, JiHS, and JoHS participated in planning and modifying the overall methods of the trial. JIP helped make the revised manuscript especially in English writing. DJC made the basic concept and major methodology of the study and planned to submit the study protocol. He had the responsibility for data quality and right to access to the data set. All authors were involved and responsible for the development of the methodology of the study. All authors are recruiting the patients and have a responsibility of the data. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study was approved by each institutional review board: Hallym University Sacred Heart Hospital (approval number 2015-II 118), Samsung Medical Center (approval number 2015-07-097), Korea University Guro Hospital (approval number KUGH 15145-001), Kyunghee University Hospital (approval number KMC IRB 1527-05), Seoul National University Hospital (approval number, 1507-059-687), Asan Medical Center (approval number 32015-1140-0001), Hanyang University Hospital (approval number 2015-07-015), Ajou University School of Medicine (approval number MED-CTA-15-209), Kangdong Sacred Heart Hospital (approval number 2015-07-012), and Seoul National University Bundang Hospital (approval number B-1507/307-005), and is being carried out in compliance with the Declaration of Helsinki.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Division of Cardiology, Hallym University Sacred Heart Hospital/Hallym University College of Medicine, 896, Pyeongchon-dong, Dongan-gu, Anyang-si, Gyeonggi-do 431-070, South Korea.
2. Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center/Sungkyunkwan University School of Medicine, #50 Inwon-dong, Gangnam-gu, Seoul 135-710, South Korea.
3. Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
4. Division of Cardioiology, KyungHee University Hospital, Seoul, South Korea.
5. Division of Cardiology, Seoul National University Hospital, Seoul, South Korea.
6. Division of Cardiology, University of Ulsan College of Medicine/Asan Medical Center, Seoul, South Korea.
7. Division of Cardiology, Hanyang University Hospital, Seoul, South Korea.
8. Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 463-707, South Korea.
9. Department of Cardiology, Ajou University School of Medicine, Suwon, South Korea.
10. Department of Internal Medicine, Kangdong Sacred Heart Hospital/Hallym University Medical Center, Seoul, South Korea.

Received: 10 December 2017 Accepted: 10 April 2018

**References**

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2223-60.
2. Slaesens JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (London, England). 2001;358:1395–5.
3. Chow CK, Teo KK, Ranganarjan S, Islam S, Gupta R, Avezam A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.
4. Kim KI, Kim HJ, Kang DH, Park JB, Choi DJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea data from Korean epidemiology study on hypertension (KEY study). Am J Hypertens. 2008;21:884–9.
5. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.
6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
7. Patsy BM, Smith NL, Sicco D, Koesell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–45.
8. Pepine CJ, Hamborg EM, Cooper-Dehoff RM, Marks RG, Nowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.
9. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
11. Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens. 2015;17(3):193–9.
12. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FERV) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–72.
13. Umemoto S, Oghara T, Matsuaki M, Rakugi H, Shimada K, Kawana M, et al. Effects of calcium-channel blocker benidipine-based combination therapy on cardiac events — subanalysis of the COPE trial. Circ J. 2017; https://doi.org/10.1253/circj.CJ-17-0592.

14. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422–7.

15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Birman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: the VALUE randomised trial. Lancet (London, England). 2004;363:2022–31.

16. Matsuaki M, Oghara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649–59.

17. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–94.

18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

19. Karotis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS, Home-Di-Plus Study G. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. Clin Exp Hypertens. 2006;28:655–62.

20. Destro M, Cikelair N, Yen J, Glazer R. Triple combination therapy with amloidipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amloidipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag. 2010;6:821–7.

21. Guideline for Evaluation and Test of Antihypertensive Drug. Ministry of Food and Drug Safety. 2009. http://www.mfds.go.kr/index.do?x=0&searchkey=title:contents&mid=695&searchword=%B0%ED%C7%F7%BE%D0&cd=&y=0&page No=1&enq=7225&cmd=v.

22. Kim K, Chang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, et al. Current status and characteristics of hypertension control in community resident elderly Korean people: data from a Korean longitudinal study on health and aging (KLoSHA study). Hypertens Res. 2008;31:97–105.

23. Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens. 2015;17:134–40.

24. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

25. Yusuf S, Diener HC, Sacco RL, Cotton O, Ourupu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.